Humacyte Inc (HUMA) concluded trading on Wednesday at a closing price of $2.00, with 25.96 million shares of worth about $51.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.76% during that period and on March 26, 2025 the price saw a loss of about -30.43%. Currently the company’s common shares owned by public are about 119.84M shares, out of which, 104.39M shares are available for trading.
Stock saw a price change of -39.58% in past 5 days and over the past one month there was a price change of -34.21%. Year-to-date (YTD), HUMA shares are showing a performance of -60.40% which decreased to -39.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.75 but also hit the highest price of $9.97 during that period. The average intraday trading volume for Humacyte Inc shares is 2.63 million. The stock is currently trading -34.50% below its 20-day simple moving average (SMA20), while that difference is down -46.21% for SMA50 and it goes to -61.84% lower than SMA200.
Humacyte Inc (NASDAQ: HUMA) currently have 119.84M outstanding shares and institutions hold larger chunk of about 33.28% of that.
The stock has a current market capitalization of $257.34M and its 3Y-monthly beta is at 1.40. It has posted earnings per share of -$1.34 in the same period. It has Quick Ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HUMA, volatility over the week remained 8.62% while standing at 9.59% over the month.
Stock’s fiscal year EPS is expected to drop by -21.63% while it is estimated to increase by 34.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 20, 2024 offering a Buy rating for the stock and assigned a target price range of between $12 and $15 to it. Coverage by H.C. Wainwright stated Humacyte Inc (HUMA) stock as a Buy in their note to investors on December 11, 2023, suggesting a price target of $6 for the stock. On August 14, 2023, Piper Sandler Upgrade their recommendations, while on June 22, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $6. Stock get an Underweight rating from Piper Sandler on May 16, 2022.
